掛號頁面

血液暨腫瘤科

血液暨腫瘤科

  • 李啟誠

    主治醫師

    血液暨腫瘤科 :
    門診掛號  

  • 現職

      • 台東馬偕紀念醫院血液暨腫瘤科主治醫師 

    主要學歷

      • 台中中國醫藥大學中醫學系醫學士
      • 國立成功大學醫學工程研究所碩士

    主要經歷

      • 美國西雅圖Fred Hutchinson Cancer Research Center研究進修醫師
      • 國立台灣大學台成幹細胞治療中心病房主任
      • 台大醫院血液科及腫瘤醫學部主治醫師
      • 第16屆中華民國血液病學會秘書長
      • 第13屆中華民國血液及骨髓移植學會秘書長

      現任:
      1.    花蓮慈濟醫院幹細胞與精準醫療研發中心主任
      2.    花蓮慈濟醫院國際醫學中心主任
      3.    花蓮慈濟醫院血液腫瘤科主治醫師
      4.    慈濟大學醫學系助理教授
        
       

主治項目或專長

MAJOR SERVICE

血液學、腫瘤學、骨髓移植、細胞治療


論文研究

  • (1) Tsai XC, Chen TT, Gau JP, Wang PN, Liu YC, Lien MY, *Li CC, Yao M, Ko BS.Outcomes of Different Haploidentical Transplantation Strategies from the Taiwan Blood and Marrow Transplantation Registry Cancers (Basel). 2022 Feb 21;14(4):1097. doi: 10.3390/cancers14041097.

  • (2) Chien SH, Yao M, *Li CC, Chang PY, Yu MS, Huang CE, Tan TD, Lin CH, Yeh SP, Li SS, Wang PN, Liu YC, Gau JP. Charlson comorbidity index predicts outcomes of elderly after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome. J Formos Med Assoc. 2021 Dec;120(12):2144-2152.
  • (3) Lee CC, Hsu TC, Kuo CC, Liu MA, Abdelfattah AM, Chang CN, Yao M, *Li CC, Wu KH, Chen TC, Gau JP, Wang PN, Liu YC, Chiou LW, Lee MY, Li SS, Chao TY, Jou ST, Chang HH. Validation of a Post-Transplant Lymphoproliferative Disorder Risk Prediction Score and Derivation of a New Prediction Score Using a National Bone Marrow Transplant Registry Database. Oncologist. 2021 Nov;26(11):e2034-e2041. doi: 10.1002/onco.13969. Epub 2021 Sep 23.
  • (4) Hsu WC, Le HN, Lin YJ, Chen MC, Wang TF, *Li CC, Kuo WW, Mahalakshmi B, Singh CH, Chen MC, Huang CY. Calmodulin/CaMKll-γ- mediates prosurvival capability in apicidin-persistent hepatocellular carcinoma cells via ERK1/2/CREB/c-fos signaling pathway J Cell Biochem. 2021 Jun;122(6):612-625.
  • (5) *Li CC, Lin CB, Chu SC, Huang WH, Lee JJ, Yang GG, Wang TF, Wu YF. Lymphocyte percentage and platelet count correlate with the treatment outcome to tyrosine kinase inhibitors in epidermal growth factor receptor-mutated lung adenocarcinoma Medicine (Baltimore) 2020 Jul 17;99(29):e21275.
  • (6) Huang WH, Tong CR, Wu T, Lin YC, *Li CC. Post-HSCT relapsed precursor B-cell ALL successfully salvaged by BiTE followed by consolidation CAR-T cell therapy: A report of two cases. Blood Cell Therapy. 2020; 3(4): 71-73. (*correspondence author)
  • (7) Wu YF, Huang WH, Gu MH, Lin SR, Chu SC, Wang TF, *Li CC.  Higher CD56+ or CD2+ lymphocyte percentage predicts poor steroid response in patients with immune thrombocytopenia. Thromb Res. 2019 Nov;183:63-68. (*correspondence author)
  • (8) Liu JH, Liao XW, Chen CH, Yao M, *Li CC, Lin CT, Tsai CH, Chou WC, Hou HA, Huang SY, Wu SJ, Chen YC, Tien HF, Tang JL, Ko BS Adoptive donor immunity protects against resolved hepatitis B virus reactivation after allogeneic haematopoietic stem cell transplantation in the world's largest retrospective cohort study. Br J Haematol. 2019 Mar 28. doi: 10.1111/bjh.15884. [Epub ahead of print]
  • (9) Lee CC, Chang HH, Lu MY, Yang YL, Chou SW, Lin DT, Jou ST, Yao M, *Li CC, Yeh SP, Chen MH, Gau JP, Li SS, Wang PN, Liu YC, Wang TF, Tan TD, Lee MY, Yu MS, Wang CC, Lin SC, Chen YC, Su YC, Su KY, Lin KH.  The incidence and risk factors of hepatic veno-occlusive disease after hematopoietic stem cell transplantation in Taiwan. Ann Hematol. 2019 Mar;98(3):745-752. 
  • (10) Tien FM, Hou HA, Tang JL, Kuo YY, Chen CY, Tsai CH, Yao M, Lin CT, *Li CC, Huang SY, Ko BS, Hsu SC, Wu SJ, Liu JH, Chou SC, Tsay W, Tseng MH, Liu MC, Liu CW, Lin LI, Chou WC, Tien HF.  Concomitant WT1 mutations predict poor prognosis in acute myeloid leukemia patients with double mutant CEBPA. Haematologica. 2018 Nov; 103(11):e510-e513. doi: 10.3324/haematol.2018.189043. Epub  2018 May 17.
  • (11) Ko BS, Wang YF, Li JL, *Li CC, Weng PF, Hsu SC, Hou HA, Huang HH, Yao M, Lin CT, Liu JH, Tsai CH, Huang TC, Wu SJ, Huang SY, Chou WC, Tien HF, Lee CC, Tang JL.  Clinically validated machine learning algorithm for detecting residual diseases with multicolor flow cytometry analysis in acute myeloid leukemia and myelodysplastic syndrome. EBioMedicine. 37 (2018) 91–100. 
  • (12) Lin CT, Hsueh PR, Wu SJ, Yao M, Ko BS, *Li CC, Hsu CA, Tang JL, Tien HF.  Repurposing nilotinib for cytomegalovirus infection prophylaxis after allogeneic hematopoietic stem cell transplantation: a single-arm, phase 2 trial. Biol Blood Marrow Transplant. 2018, 24 (11): 2310-2315.
  • (13) Tien FM, Hou HA, Tsai CH, Tang JL, Chen CY, Kuo YY, *Li CC, Lin CT, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Tseng MH, Liu MC, Liu CW, Lin LI, Chou WC, Tien HF. Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients. Eur J Haematol. 2018, 101(1): 86-94.
  • (14) Lin ME, Hou HA, Tsai CH, Wu SJ, Kuo YY, Tseng MH, Liu MC, Liu CW, Chou WC, Chen CY, Tang JL, Yao M, *Li CC, Huang SY, Ko BS, Hsu SC, Lin CT, Tien HF. Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome. Clin Epigenetics. 2018 Apr 2;10:42. doi: 10.1186/s13148-018-0476-1. eCollection 2018.
  • (15) Chu SC, Tang JL,*Li CC. Dasatinib in chronic myelogenous leukemia. N Engl J Med 2006; 355 (10):1062-3. (*correspondence author)